697 related articles for article (PubMed ID: 26470536)
1. [Recent Advances in Vaccines and Drugs Against the Ebola Virus].
Zhu X; Yao C; Wei Y; Kou Z; Hu K
Bing Du Xue Bao; 2015 May; 31(3):287-92. PubMed ID: 26470536
[TBL] [Abstract][Full Text] [Related]
2. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
Mire CE; Matassov D; Geisbert JB; Latham TE; Agans KN; Xu R; Ota-Setlik A; Egan MA; Fenton KA; Clarke DK; Eldridge JH; Geisbert TW
Nature; 2015 Apr; 520(7549):688-691. PubMed ID: 25853476
[TBL] [Abstract][Full Text] [Related]
3. Ebola Virus: Pathogenesis and Countermeasure Development.
Furuyama W; Marzi A
Annu Rev Virol; 2019 Sep; 6(1):435-458. PubMed ID: 31567063
[TBL] [Abstract][Full Text] [Related]
4. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.
Mire CE; Geisbert JB; Marzi A; Agans KN; Feldmann H; Geisbert TW
PLoS Negl Trop Dis; 2013; 7(12):e2600. PubMed ID: 24367715
[TBL] [Abstract][Full Text] [Related]
5. Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus.
Dhama K; Karthik K; Khandia R; Chakraborty S; Munjal A; Latheef SK; Kumar D; Ramakrishnan MA; Malik YS; Singh R; Malik SVS; Singh RK; Chaicumpa W
Front Immunol; 2018; 9():1803. PubMed ID: 30147687
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the development of vaccines for Ebola virus disease.
Ohimain EI
Virus Res; 2016 Jan; 211():174-85. PubMed ID: 26596227
[TBL] [Abstract][Full Text] [Related]
7. Correlates of vaccine-induced protective immunity against Ebola virus disease.
Medaglini D; Santoro F; Siegrist CA
Semin Immunol; 2018 Oct; 39():65-72. PubMed ID: 30041831
[TBL] [Abstract][Full Text] [Related]
8. Development of therapeutics for treatment of Ebola virus infection.
Li H; Ying T; Yu F; Lu L; Jiang S
Microbes Infect; 2015 Feb; 17(2):109-17. PubMed ID: 25498866
[TBL] [Abstract][Full Text] [Related]
9. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.
Ewer K; Rampling T; Venkatraman N; Bowyer G; Wright D; Lambe T; Imoukhuede EB; Payne R; Fehling SK; Strecker T; Biedenkopf N; Krähling V; Tully CM; Edwards NJ; Bentley EM; Samuel D; Labbé G; Jin J; Gibani M; Minhinnick A; Wilkie M; Poulton I; Lella N; Roberts R; Hartnell F; Bliss C; Sierra-Davidson K; Powlson J; Berrie E; Tedder R; Roman F; De Ryck I; Nicosia A; Sullivan NJ; Stanley DA; Mbaya OT; Ledgerwood JE; Schwartz RM; Siani L; Colloca S; Folgori A; Di Marco S; Cortese R; Wright E; Becker S; Graham BS; Koup RA; Levine MM; Volkmann A; Chaplin P; Pollard AJ; Draper SJ; Ballou WR; Lawrie A; Gilbert SC; Hill AV
N Engl J Med; 2016 Apr; 374(17):1635-46. PubMed ID: 25629663
[TBL] [Abstract][Full Text] [Related]
10. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
[TBL] [Abstract][Full Text] [Related]
11. New Advances in the Effort against Ebola.
Saphire EO
Cell Host Microbe; 2015 May; 17(5):545-7. PubMed ID: 25974296
[TBL] [Abstract][Full Text] [Related]
12. Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection.
Tshiani Mbaya O; Mukumbayi P; Mulangu S
Front Immunol; 2021; 12():721328. PubMed ID: 34526994
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.
Henao-Restrepo AM; Longini IM; Egger M; Dean NE; Edmunds WJ; Camacho A; Carroll MW; Doumbia M; Draguez B; Duraffour S; Enwere G; Grais R; Gunther S; Hossmann S; Kondé MK; Kone S; Kuisma E; Levine MM; Mandal S; Norheim G; Riveros X; Soumah A; Trelle S; Vicari AS; Watson CH; Kéïta S; Kieny MP; Røttingen JA
Lancet; 2015 Aug; 386(9996):857-66. PubMed ID: 26248676
[TBL] [Abstract][Full Text] [Related]
14. [Ebola : an uncontrolled outbreak despite vaccines and new treatments].
Vetter P; Kaiser L
Rev Med Suisse; 2020 Apr; 16(690):739-743. PubMed ID: 32301308
[TBL] [Abstract][Full Text] [Related]
15. Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine.
Farooq F; Beck K; Paolino KM; Phillips R; Waters NC; Regules JA; Bergmann-Leitner ES
Sci Rep; 2016 Jun; 6():27944. PubMed ID: 27323685
[TBL] [Abstract][Full Text] [Related]
16. Progress towards a vaccine against Ebola to meet emergency medical countermeasure needs.
Wolfe DN; Zarrabian AG; Disbrow GL; Espeland EM
Vaccine; 2019 Nov; 37(48):7178-7182. PubMed ID: 29199040
[TBL] [Abstract][Full Text] [Related]
17. Assessing Antiviral Countermeasures Using Mouse Models of Ebolavirus Infection.
Kroeker A; Griffin BD; Qiu X; Kobinger G
Methods Mol Biol; 2017; 1628():273-282. PubMed ID: 28573628
[TBL] [Abstract][Full Text] [Related]
18. Basic science and the Ebola virus infection epidemic.
DeVane CL
Pharmacotherapy; 2014 Nov; 34(11):1115-7. PubMed ID: 25382095
[No Abstract] [Full Text] [Related]
19. [Ebola vaccine and treatment].
Takada A
Uirusu; 2015; 65(1):61-70. PubMed ID: 26923959
[TBL] [Abstract][Full Text] [Related]
20. Immunomonitoring of human responses to the rVSV-ZEBOV Ebola vaccine.
Medaglini D; Siegrist CA
Curr Opin Virol; 2017 Apr; 23():88-94. PubMed ID: 28460340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
